Reclast offers consistent vertebral* fracture protection Years 1 through 3
Significant Increases in BMD vs Placebo at 3 Years
6.7% increase at lumbar spine (P<0.001)
6.0% increase at hip (P<0.001)
5.1% increase at femoral neck (P<0.001)
*Nonclinical (asymptomatic) morphometric vertebral fractures (defined as a reduction in vertebral height of at least 20% and 4 mm by quantitative morphometry, confirmed by an increase of one severity grade or more on semiquantitative analysis).
